Germline Testing for Prostate Cancer Patients: Evidence‐Based Evaluation of Genes Recommended by NCCN Guidelines

20254 citationsJournal Articlehybrid Open Access

Authors

Jianfeng Xu · University of Chicago

Jim Lu · SignPath Pharma (United States)

Marta Gielzak · Johns Hopkins Hospital

S. Lilly Zheng · Center for Genomic Science

Lucy Lu · SignPath Pharma (United States)

Jun Wei · Center for Genomic Science

Brandon Cornell ·

Abstract

Supporting statistical evidence is available for only a subset of the NCCN-recommended genes for germline testing. This evidence-based analysis may aid urologists-particularly those without specialized genetics training-in understanding germline testing for PCa risk assessment, prognosis, and treatment decision-making in clinical practice.

Topics & Keywords

Prostate Cancer Treatment and Research PARP inhibition in cancer therapy Prostate Cancer Diagnosis and Treatment

Publication Details

Published in: The Prostate

Volume 85, Issue 12, pp. 1087-1095

DOI: 10.1002/pros.24918

Field-Weighted Citation Impact: 6.14

Command Palette

Germline Testing for Prostate Cancer Patients: Evidence‐Based Evaluation of Genes Recommended by NCCN Guidelines

Authors

Abstract

Topics & Keywords

Publication Details